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Saxena, Rajesh, Kumar, Talwar, Subramania
(left to right)doi:10.1016/j.jtcvs.2004.11.006Objective: The purpose of this study was to assess the long-term results of
mitral valve repair in children with chronic rheumatic heart disease.
Methods: From January 1988 through December 2003, 278 children (153 male
children) underwent mitral valve repair. Mean age was 11.7  2.9 years (range,
2-15 years). One hundred seventy-three children (62%) were in the New York
Heart Association functional class III or IV. Congestive heart failure was present in
24 (8.6%). Reparative procedures included posterior collar annuloplasty (n 242),
commissurotomy (n 187), cusp-level chordal shortening (n 94), cusp thinning
(n 71), cleft suture (n 65), and cusp excision or plication (n 10). Associated
procedures included atrial septal defect closure (n  22), aortic valve repair/
replacement (n  13), and tricuspid valve repair (n  3).
Results: Early mortality was 2.2% (6 patients). Preoperative left ventricular dys-
function was associated with greater mortality. Median follow-up was 56.5 months
(mean, 58.9.  32.3 months; range, 5 to 180 months). One hundred seventy-seven
survivors (65%) had no or trivial mitral regurgitation. Sixteen patients (6%) required
reoperation for valve dysfunction. There were 7 late deaths (2.6%). Actuarial,
reoperation-free, and event-free survivals at a median follow-up of 56.5 months
were 95.2%  1.5%, 91.6%  2.2%, and 55.9%  3.5%, respectively; at 15 years,
they were 95.2%  1.5%, 85.9%  5.9%, and 46.7%  4.7%, respectively.
Conclusion: Mitral valve repair in children with chronic rheumatic heart disease is
feasible and provides acceptable long-term results.
Experience with mitral valve repair in the rheumatic population islimited.1-6 Major hindrances to the less-frequent repairs in thispopulation have been the unpredictability of long-term results and,more important, the complexity of the disease process, which makeit difficult to choose the appropriate procedure for any given patient.7In 1995, we reported our initial experience with mitral valve
reconstruction in 125 children operated on between 1988 and 1994.8 We now
present detailed results with long-term follow-up.
Patients and Methods
From January 1988 through December 2003, 1022 patients underwent mitral valve recon-
struction at our institution. We studied 278 (27.2%) of these patients who were 15 years of
age or younger. Of these 278 patients, 153 (55%) were male. The mean age at surgery was
11.7  2.9 years (range, 2-15 years). All patients had evidence of rheumatic heart disease.
Pure mitral regurgitation (MR) was present in 123 (44%) patients, and combined mitral
stenosis (MS) and MR was present in 155 (56%) patients. Atrial fibrillation (AF) was present
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was dyspnea on exertion. One hundred seventy-three patients
(62%) were in New York Heart Association (NYHA) functional
class III or IV. Congestive heart failure (CHF) was present in 24
(8.6%) patients.
Preoperative transthoracic echocardiography was performed in
all patients. Cardiac catheterization and cineangiography were
performed on suspicion of associated aortic valve disease. MR was
graded by Doppler echocardiography or angiography or by both
according to previously published criteria.9,10 After January 1994,
intraoperative transesophageal echocardiography was performed
with a Hewlett- Packard Sonos 1500, 2500, or 5500 ultrasonog-
raphy system. (Hewlett-Packard Co, Andover, Mass). Echocardio-
graphic assessment included the annulus, leaflet thickness and
mobility, commissural and chordal fusion, presence of calcifica-
tion, regurgitant jet, thickness of the chordae tendineae, and the
presence of clots in the left atrium or the left atrial appendage.
Other valves were also assessed in a systematic fashion.
Surgical Technique
Surgical approach was via a median sternotomy (n  219) or, in
female patients, a right anterolateral thoracotomy (n  59) purely
for cosmetic reasons. Aorto-bicaval cannulation was used in all
patients. Before 1996, moderately hypothermic (32°C) cardiopul-
monary bypass (CPB) was used. Since 1996, normothermic per-
fusion has been used in all patients. Antegrade cold blood cardio-
plegia and topical ice slush were used for myocardial production.
The mitral valve was exposed through a standard incision in the
left atrial wall behind the interatrial groove. In patients with an
associated atrial septal defect (ASD), the approach was through the
right atrium. After careful evaluation of the mitral valve, a variety
of reparative procedures developed by us and described in detail in
our previous publications5,8,11-13 was used. The procedures in-
cluded posterior collar annuloplasty11 (n  242), commissurotomy
(n  187), cusp-level chordal shortening (n  94), cusp thinning
(n 71), cleft suture (n 65), cusp excision or plication (n 10),
decalcification (n 3), and chordal transfer (n 3). No procedure
was performed for correction of AF.
Associated procedures included atrial septal defect closure in
22 patients, aortic valve repair in 8, aortic valve replacement in 5,
and tricuspid valve repair in 3. At the completion of repair, mitral
valve competence was tested by using a bulb syringe to inject cold
saline into the left ventricular cavity with the aortic root vent open,
and coaptation of leaflets was observed. Since 1994, transesoph-
ageal echocardiography has been used for assessment of repairs.
Follow-up
Transthoracic echocardiography was carried out in all patients
before discharge from the hospital and repeated at 6 monthly
intervals. Before 1998, all patients undergoing posterior collar
annuloplasty were prescribed acenocoumarin for 6 weeks and
dipyridamole for 6 months. Since April 1998, this practice has
been discontinued. All patients were seen in the outpatient clinic at
our hospital. The results of their clinical status and echocardio-
grams between January 2004 and July 2004 were recorded and are
reported in this study.
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Data were analyzed with the SPSS 10.0 for Windows software
package (SPSS Inc, Chicago Ill). Mean, median, and standard
deviation were calculated for continuous variables. Univariate
analysis was performed with the 2 and Fisher exact tests. Actu-
arial estimates were calculated and compared by using the Kaplan-
Meier analysis with Mantel-Cox log-rank tests. MR was consid-
ered to be significant if it was moderate or severe. Factors analyzed
as predictors of early and late mortality and of development of
significant MR included age, sex, type of lesion (MR or mixed),
preoperative NYHA class, preoperative CHF, presence of AF,
valve pathology (cusp prolapse, annular dilatation, chordal elon-
gation, chordal rupture, calcification of valve leaflets), left ventric-
ular dysfunction (ejection fraction  50%, n  24), associated
aortic and tricuspid valve disease, CPB and aortic crossclamp time,
and various reparative techniques. All factors were subjected to
multiple logistic regression analysis to determine the independent
predictors of early mortality. The Cox proportional hazards model
was used to determine the prognostic factors for significant MR.
Results
Early Mortality
All patients survived the operation. Mean aortic crossclamp
time was 37.2  12.8 minutes (range, 23-66 minutes), and
the mean CPB time was 47.6  11.9 minutes (range, 36-83
minutes) for patients who underwent mitral valve repair
alone. Fifteen patients (5.4%) required inotropic support.
Median duration of mechanical ventilation was 18 hours
(range, 9-68 hours). Mean hospital stay was 5.8  1.7 days
(range, 4-29 days). There were 6 early deaths (2.2%), which
were encountered in the first 125 patients and reported by us
earlier.8 Of these deaths, 5 were due to persistent low
cardiac output caused by severe left ventricular dysfunction,
and 1was due to cerebral infarction. No in-hospital deaths
occurred in the last 153 consecutive patients.
Late Outcome
Follow-up was 98% complete (n  266) and ranged from 5
to 180 months (mean, 58.9  33.3 months; median, 56.5
months). Total follow-up was 1335 patient-years. Among
survivors, 19 (7%) were followed up for 15 or more years,
25 (9%), for 10 or more years, 116 (43%), for more than 5
years, and 210 (77%), for more than 3 years. We followed
standard published guidelines14 in reporting freedom from
valve-related events.
Thromboembolic complications. Four patients (1.5%)
had a thromboembolic complication (0.3 events per 100
patient-years) in the late postoperative period at a mean
follow-up of 24  24.4 months (range, 3-56 months). One
of these patients died 3 months after surgery; the rest
recovered uneventfully. Of the 4 patients, 3 had persistent
AF.
Hemolysis. Sixteen patients had significant hemolysis
(1.2 events per 100 patient-years) Nine of these had signif-
icant MR: two underwent MVR, 2 died without undergoing
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ing 7 patients, 2 were lost to follow-up, and hemolysis
gradually subsided in the other 5.
Infective endocarditis. One patient had subacute bacte-
rial endocarditis. He was treated conservatively and is well
32 months after initial surgery.
Reoperation. Sixteen patients underwent reoperation for
severe valve dysfunction (1.2 events per 100 patient-years)
after a mean period of 39.13  31.2 months (range, 3-132
months). Freedom from reoperation was 91.6%  2.2% at
56.5 months and 85.9%  5.9% at 15 years (Figure 1). One
patient underwent repeat mitral valve repair within 3
months due to dehiscence of the annuloplasty ring. Another
patient underwent mitral valve replacement (MVR) with a
cryopreserved mitral homograft 18 months after initial sur-
gery; however, 24 months after MVR, he continued to have
recurrent attacks of rheumatic fever with severe aortic re-
gurgitation and MR for which he underwent prosthetic
double-valve replacement. Of the other 14 patients, 2 un-
derwent repeat mitral valve repair, and the rest underwent
MVR. Two of the latter died postoperatively of low cardiac
output.
Apart from the patient in whom dehiscence of the annu-
loplasty felt developed, the remaining patients had evidence
of progression of the disease, with new thickening of the
cusps and subvalvular fusion. Twelve of these patients had
mixed MR and MS as the initial lesion.
Valve function. Of the 272 survivors, 177 (65%) had no
or trivial to mild MR at last follow-up. The remaining 95
patients (35%) had significant MR after a median period of
34 months (mean, 35.6  34.5 months), which was mod-
erate in 52 (19.1%) and severe in 43 patients (15.9%).
Fourteen patients with severe MR underwent reoperation; 3
died as a result of persistent CHF. Freedom from develop-
ment of significant MR was 55.9%  3.5% at a median of
56.5 months and 46.7%  4.7% at 15 years. Multivariate
analysis of risk factors for significant MR showed a high
probability in patients with mixed (regurgitant and stenotic)
lesions (hazard ratio, 1.72; 95% confidence interval, 1.25-
2.5; P  .006) and in patients with significant left ventric-
ular dysfunction (hazard ratio, 4.9; 95% confidence interval,
2.65-9.2; P.005.)
Severe MS developed in 3 patients: two underwent re-
operation, and 1 was lost to follow-up.
Functional class. One hundred seventy-seven patients
with insignificant MR are in NYHA class I. Of the 52
patients with moderate MR, 46 are free of symptoms, 4 are
in NYHA class II-III due to development of aortic valve
disease, and 2 are in NYHA class III due to left ventricular
dysfunction. Of the 43 patients with severe MR, 19 were in
NYHA class III or IV: fourteen of the latter underwent
reoperation, and 5 died due to persistent CHF. The remain-
ing 24 patients are in either NYHA class I or II. Of the 3
The Journal of Thoracipatients with severe MS, 2 were in NYHA class IV and
underwent reoperation, and 1 was lost to follow-up. A total
of 160 patients (60%) are in normal sinus rhythm.
Late deaths and survival. There were 7 late deaths
(2.6%) after a median period of 18 months (mean, 31 
41.2 months; range, 2.2 to 118 months). Two patients died
at reoperation: 3 due to persistent CHF while awaiting
reoperation, 1 due to cerebrovascular accident, and 1 due to
acute viral hepatitis.
Actuarial survival in the 278 patients was 95.2% 1.5%
at 56.5 months and was similar at 15 years. In patients with
left ventricular dysfunction, the survival at 56.5 months was
63.8%  14.9% compared with 99%  0.1% in patients
with normal left ventricular function. Left ventricular func-
tion was an independent predictor of late death (P  .017).
Event-free survival in survivors was 55.9%  3.5% at 56.5
months and 46.7%  4.7% at 15 years (Figure 2).
Discussion
Two thirds of patients with rheumatic heart disease in
developing countries are of school age.15 Because of recur-
rent rheumatic fever, a large proportion of these patients
have chronic rheumatic mitral valve disease requiring sur-
gery. Valve replacement is not the best option in these
patients because of (1) higher mortality compared with
Figure 1. Freedom from reoperation (Kaplan-Meier) in children
after mitral valve repair.
Time interval (mo) 0 12 36 60 120 180
Patients at risk 272 202 156 110 25 19
Freedom from
reoperation (%)
100 96.7 92.7 91.7 85.9 85.9
Standard error 0 1.2 1.9 2.1 5.9 5.9adults; (2) small size of the implanted valve due to smaller
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thromboembolism, and bleeding; (4) rapid degeneration of
the available bioprosthesis in the young population; (5)
higher risk of endocarditis; and (6) suboptimal preserva-
tion of ventricular function and reduced long-term sur-
vival.5-8,16,17 Because of these problems, mitral valve repair
is the procedure of choice for MR in the young.5-8,16-21
Repair is technically more difficult in this group of
patients, and the failure rates are higher, with reoperation
rates between 5% to 27% compared with the 8% to 10% rate
in the adult population at 5 years of follow-up.6-8,17-20 In
one large series, it was found that the rate of repair was
inversely related to the age of the patient: At maximum
follow-up of 52 months, the reoperation rate in this series
was 23.6% in patients 20 years of age or younger compared
with 9.6% in older patients.5 In our early experience, the
reoperation rate was 5.98%8 in this study, it was 6% at a
longer follow-up. Rheumatic etiology, mixed lesions, thick-
ened cusps, and younger age have been associated with an
early rate of valve failure.4-6,16,18-20 In an earlier study of
more than 800 patients of all age groups undergoing mitral
valve repair at our institution, we found that only younger
age, left ventricular dysfunction, mixed lesions, and the
need for cuspal thinning were independent risk factors for
development of significant MR;5 however, in the present
study, only left ventricular dysfunction and mixed lesions
Figure 2. Event-free survival (Kaplan-Meier) in children after
mitral valve repair.
Time interval (mo) 0 12 >36 60 120 180
Patients at risk 272 195 95 67 25 15
Actuarial survival (%) 100 80.4 58.7 55.7 46.7 46.7
Standard error 0 2.4 3.3 3.5 4.7 4.7were independent risk factors in the younger population.
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was higher (Figure 3) in the immediate postoperative phase
and remained constant for the first 18 months of follow-up.
This plateau was followed by a gradual rise up to 6 years,
followed by intermittent peaks and a plateau after 10 years
of follow-up. This finding correlates with our previous
observation that the early peak could be due to suboptimal
repair.5 The later peaks may be due to recurrence and
progression of rheumatic activity.
The results of MVR in children are inferior to those of
mitral valve repair. In a report of 90 children undergoing
MVR, the in-hospital mortality was 19% with 6 throm-
boembolic events and 9 bleeding complications on fol-
low-up.7 In a large study of the long-term results of
mitral valve repair in 254 young patients with chronic
rheumatic MR, the operative mortality was 2.6%, late
mortality was 15%, and the reoperation rate was 27% at
5 years of follow-up.4 In contrast, we observed an oper-
ative mortality of 2.2% and a late mortality of only 2.6%.
Mitral valve repair is thus clearly superior to MVR. A
large number of these young patients enjoy a carefree
childhood and adolescence and have children before re-
turning for reoperation. The reoperation rates in patients
undergoing initial repair or replacement are similar,
which favors repair as an option.
Conclusion
Mitral valve repair in children with rheumatic heart disease
is feasible and provides acceptable long-term results.
We thank Dr Rajvir Singh, PhD (Biostatistics), for statistical
Figure 3. Instantaneous risk (hazard function) for development of
significant mitral regurgitation across time after mitral valve
repair.analysis.
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